Your homocysteine is elevated.

Folate and vitamin B12 may appear adequate, yet the result remains unchanged.

Perhaps a genetic report highlights BHMT, PEMT, or CHDH variants. Perhaps an online calculator estimates that you need the equivalent of several egg yolks every day. Or perhaps TMG lowered your homocysteine, improved your energy, or made you feel anxious, depressed, overstimulated, or unable to sleep.

The common explanation is:

“TMG bypasses MTHFR, so a response proves that the BHMT pathway was impaired.”
The real interpretation is more limited.

Choline can be converted into betaine. Betaine can donate a methyl group to homocysteine through the enzyme betaine-homocysteine methyltransferase, or BHMT. Human intervention studies show that betaine can lower plasma homocysteine.

However, there is no validated clinical test that diagnoses: “Choline/Betaine-Dependent Remethylation Impairment.”

Routine laboratory tests do not measure real-time BHMT flux. A common BHMT variant does not show that the enzyme is blocked. Low plasma choline does not prove that all tissues are choline deficient. A fall in homocysteine after TMG does not establish why homocysteine was elevated.

This pattern therefore asks a more useful question:

Do the dietary, laboratory, genetic, and response findings make limited choline or betaine availability a plausible contributor to elevated homocysteine, or is another explanation more convincing?

The combinations below are educational examples. They are not diagnostic criteria, and the same laboratory result may have several causes.

The limited-availability hypothesis becomes more plausible when:

• fasting homocysteine is reproducibly elevated;
• folate and vitamin B12 have been assessed adequately;
• kidney and thyroid function do not provide a stronger explanation;
• dietary choline or betaine exposure is plausibly low;
• plasma betaine is low or marginal under interpretable conditions;
• liver function does not make the pattern difficult to interpret;
• an objective homocysteine response occurs after a documented intervention while other relevant variables remain stable.

The more of these features align, the stronger the case for a betaine-responsive contribution.
Even then, the available evidence does not create a formal diagnosis of BHMT impairment.

Homocysteine is a normal intermediate in methionine metabolism.

It can be directed into two broad pathways:

1. remethylation back to methionine;
2. transsulfuration toward cystathionine and downstream sulfur metabolites.

There are two major remethylation routes relevant to this pattern.

Methionine synthase converts homocysteine into methionine using:

• 5-MTHF as the methyl donor;
• vitamin B12 as a cofactor.

This pathway operates broadly across tissues.

BHMT converts:

betaine + homocysteine → dimethylglycine + methionine

In this reaction:

• betaine provides the methyl group;
• homocysteine becomes methionine;
• dimethylglycine, or DMG, is produced;
• BHMT functions as a zinc-dependent enzyme.

BHMT expression is concentrated particularly in the liver and kidney.
This tissue distribution matters.

A reduction in plasma homocysteine after betaine can show that hepatic and renal betaine-dependent remethylation contributed to handling the circulating homocysteine pool.

It does not demonstrate that:

• folate-dependent remethylation has been restored;
• MTHFR activity has normalized;
• vitamin B12 is no longer relevant;
• remethylation has increased equally in every tissue;
• brain methylation has been corrected;
• neurotransmitter metabolism has been normalized;
• every symptom was caused by homocysteine.

Evidence: [A1, B1, B2].

Betaine can enter the pathway through two main routes.

Dietary betaine

Betaine is naturally present in foods, including:

• wheat products;
• wheat bran and wheat germ;
• beets;
• spinach;
• quinoa;
• selected grains and plant foods.

The amount varies considerably according to the food, agricultural conditions, processing, and serving size.

Oxidation of choline

Choline can be oxidized in two steps:

choline → betaine aldehyde → betaine

The conversion is effectively irreversible.

Once choline has been converted into betaine, that molecule is no longer available for:

• phosphatidylcholine synthesis;
• acetylcholine synthesis;
• sphingomyelin synthesis;
• other structural choline functions.

This is why choline and betaine overlap, but are not interchangeable.
Betaine can support the methyl-donor function of choline.
It cannot replace all the other biological roles of choline.

The phrase is partly useful and partly misleading.

What it can mean

Betaine provides a methyl group to homocysteine through BHMT without requiring:

• MTHFR-generated 5-MTHF;
• vitamin B12-dependent methionine synthase for that specific reaction.

In this limited sense, BHMT provides an alternative route around the folate-dependent remethylation reaction in tissues where BHMT is active.

What it does not mean

TMG does not:

• repair an MTHFR variant;
• produce 5-MTHF;
• replenish the folate pool;
• correct a methylfolate trap;
• replace vitamin B12;
• restore folate-dependent reactions in all tissues;
• prove that MTHFR was responsible for elevated homocysteine;
• establish normal methylation in the brain;
• make folate or B12 assessment unnecessary.

A lower plasma homocysteine result shows that the alternative route can respond to additional betaine.
It does not establish why the original elevation occurred.

Interpretive takeaway

TMG can provide an alternative substrate for homocysteine remethylation. It does not restore the entire folate-B12 pathway.

No.

Homocysteine is influenced by:

• folate;
• vitamin B12;
• vitamin B6;
• riboflavin;
• kidney function;
• thyroid function;
• age;
• smoking;
• alcohol exposure;
• methionine intake;
• physical activity;
• selected medications;
• liver and metabolic disease;
• rare inherited disorders;
• several factors acting together.

Low choline or betaine availability is therefore one possible contributor, not the default explanation.

The hypothesis becomes more relevant when:

• folate is adequate;
• B12 deficiency is not strongly supported;
• kidney function is preserved;
• hypothyroidism is not a better explanation;
• dietary exposure is limited;
• plasma betaine is low or marginal;
• homocysteine responds reproducibly to betaine under stable conditions.

It becomes less convincing when:

• folate deficiency is clear;
• B12 deficiency is clear;
• eGFR is reduced;
• liver disease substantially alters methionine metabolism;
• homocysteine is consistently normal;
• dietary exposure and plasma betaine are adequate;
• substantial betaine exposure does not change the objective pattern;
• the interpretation rests mainly on symptoms or SNP reports.

A BHMT, PEMT, or CHDH variant can provide biological context.

It does not automatically create a supplement requirement.

When the available findings include:

• normal fasting homocysteine;
• no evidence of choline deficiency;
• no relevant liver or muscle abnormality;
• no established nutritional inadequacy;
• only nonspecific symptoms;
• a common genetic variant,

there is not enough evidence to diagnose BHMT-dependent remethylation impairment.

Normal homocysteine does not show that every aspect of choline metabolism is optimal.

Choline still has essential structural, hepatic, neurological, and developmental functions.

However, the absence of a compatible homocysteine phenotype means that the main measurable feature of this pattern has not been demonstrated.

Interpretive takeaway

A variant may identify a potential difference in metabolism. It does not show that a pathway is currently failing.

A fall in homocysteine supports the conclusion that circulating homocysteine was responsive to additional betaine.

The response is more interpretable when:

• fasting homocysteine was elevated on more than one occasion;
• the betaine product, dose, and duration were documented;
• folate and B12 exposure remained stable;
• kidney and thyroid function remained stable;
• diet did not change substantially;
• no new homocysteine-lowering supplement was introduced;
• the same laboratory and comparable testing conditions were used.

The response does not prove that:

• the person was betaine deficient;
• BHMT was genetically impaired;
• BHMT was the main bottleneck;
• dietary choline was inadequate;
• MTHFR was bypassed in every tissue;
• methylation was globally restored;
• the original homocysteine elevation had only one cause;
• symptoms were caused by elevated homocysteine;
• the same exposure should continue indefinitely;
• a larger dose would provide a better outcome.

Homocysteine also has biological and analytical variability.

A controlled before-and-after comparison is stronger than a single result, but it remains evidence of responsiveness, not proof of a unique diagnosis.

Several explanations are possible.

1. Choline or betaine availability was not the main limitation

The pathway may already have had adequate substrate.

2. Folate remains inadequate

Betaine-dependent remethylation may not fully compensate for limited folate-dependent metabolism.

3. Vitamin B12-dependent methionine synthase remains limited

A person can have more than one remethylation limitation.

4. Kidney function is contributing

Reduced renal function can maintain elevated homocysteine despite changes elsewhere in the network.

5. Thyroid, medication, smoking, alcohol, or metabolic factors remain active

The pattern may be mixed.

6. The baseline result was not reproducible

A small apparent elevation may reflect ordinary variation, nonfasting conditions, recent diet, or laboratory differences.

7. The exposure was not clearly documented

Products can differ in:

• actual betaine content;
• serving size;
• salt form;
• added ingredients;
• adherence;
• timing.

8. Several interventions were introduced together

If TMG, choline, methylfolate, B12, B6, creatine, and diet changed simultaneously, the result cannot be assigned to one factor.

9. The expected outcome was a symptom rather than homocysteine

A product may change homocysteine without improving:

• fatigue;
• anxiety;
• mood;
• sleep;
• cognition;
• exercise tolerance;
• gastrointestinal symptoms.

Interpretive takeaway

Failure of the objective marker to change should weaken or complicate the original substrate-limitation hypothesis.

It does not automatically establish a need for:

• more TMG;
• a different choline form;
• methylfolate;
• SAMe;
• additional methyl donors;
• a larger supplement stack.

The tests below can provide pieces of evidence.

None of them, alone or in combination, diagnoses a formal BHMT-dependent remethylation disorder.

Fasting homocysteine is the most accessible marker for identifying a reproducible remethylation-related pattern.

Most useful for

• identifying persistent elevation;
• following an objective response;
• placing dietary and genetic findings into metabolic context.

It does not identify

• which nutrient is limiting;
• BHMT enzyme activity;
• folate-dependent versus betaine-dependent flux;
• choline deficiency;
• the cause of symptoms;
• methylation activity in the brain;
• cardiovascular risk in isolation.

Testing considerations

Interpretation improves when:

• fasting conditions are comparable;
• the same laboratory is used;
• recent supplements are documented;
• kidney function is known;
• folate and B12 have been assessed;
• major medication and lifestyle changes are recorded.

Plasma betaine can be measured by specialized laboratories.

It may reflect:

• recent dietary intake;
• supplemental exposure;
• endogenous production from choline;
• renal handling;
• hepatic utilization;
• metabolic context.

Potential value

A low or marginal result may increase the plausibility of limited betaine availability, particularly when dietary intake is also low.

A rise after supplementation can confirm exposure.

Important limitations

Plasma betaine does not directly measure:

• BHMT activity;
• intracellular betaine in all tissues;
• the rate of methyl transfer to homocysteine;
• whether low availability is the main cause of elevated homocysteine;
• the dose required for one person;
• whether symptoms will respond.

Reference intervals and testing methods can vary.

There is no universally accepted plasma betaine threshold that diagnoses a BHMT bottleneck

Dimethylglycine is produced when BHMT transfers a methyl group from betaine to homocysteine.
This makes DMG biochemically relevant.

A change in DMG after betaine exposure may indicate that betaine metabolism has changed.

However, DMG concentrations are influenced by:

• betaine availability;
• BHMT flux;
• downstream DMG metabolism;
• kidney function;
• folate-related metabolism;
• recent diet and supplementation.

A high DMG result does not prove excessive methylation.
A low DMG result does not prove that BHMT is blocked.

No validated clinical algorithm uses a single DMG result to diagnose:

• betaine deficiency;
• BHMT impairment;
• the correct TMG dose;
• the cause of psychiatric or neurological symptoms.

BHMT produces methionine.

Methionine may therefore provide additional context when measured with homocysteine, betaine, and DMG.

However, plasma methionine is affected by:

• dietary protein;
• fasting duration;
• liver metabolism;
• genetic disorders;
• general amino-acid metabolism.

A normal methionine result does not exclude a betaine-responsive component.
A high result after betaine does not demonstrate beneficial whole-body methylation.

Low folate can raise homocysteine independently.

A betaine response does not make folate irrelevant.

Useful context can include:

• serum folate;
• RBC folate in selected settings;
• dietary intake;
• fortified-food exposure;
• recent supplementation.

A high serum folate result during supplementation does not reconstruct the person’s status before supplementation.

The folate-dependent conversion of homocysteine into methionine requires vitamin B12.

Useful context may include:

• serum B12;
• methylmalonic acid;
• holotranscobalamin where available;
• CBC and MCV;
• diet;
• medications;
• absorption risk.

TMG may lower circulating homocysteine even when a B12-related problem remains present.
A homocysteine response should therefore not be used to dismiss possible B12 deficiency.

Kidney function strongly influences circulating homocysteine.

The kidney is also one of the tissues in which BHMT is relevant.

Reduced kidney function can alter:

• homocysteine;
• betaine;
• DMG;
• TMAO;
• interpretation of the entire pattern.

Persistent homocysteine elevation should not be attributed primarily to limited choline or betaine availability without considering creatinine and eGFR.

BHMT is highly expressed in the liver.

Choline is also essential for:

• phosphatidylcholine synthesis;
• cell-membrane integrity;
• VLDL assembly and lipid export;
• normal hepatic lipid metabolism.

Relevant context may include:

• ALT;
• AST;
• GGT;
• bilirubin;
• alkaline phosphatase;
• triglycerides;
• metabolic markers;
• imaging when clinically indicated.

These tests do not measure BHMT directly.
Normal liver enzymes also do not exclude every form of hepatic steatosis.

A dietary estimate may help identify:

• very low egg, meat, fish, dairy, or soy intake;
• limited intake of betaine-rich grains and vegetables;
• restrictive vegan or elimination diets;
• low total food intake;
• avoidance of major choline sources without replacement;
• changes related to pregnancy, illness, or food intolerance.

Dietary databases provide estimates, not exact personal absorption.
A calculated intake below an Adequate Intake does not prove deficiency.
An intake above the Adequate Intake does not guarantee adequate status in every person.

Genetic testing can identify common variants in:

• BHMT;
• PEMT;
• CHDH;
• MTHFR;
• MTHFD1;
• other genes connected to one-carbon and choline metabolism.

It does not measure:

• present enzyme activity;
• dietary intake;
• plasma betaine;
• current homocysteine flux;
• liver function;
• total-body choline status;
• an individual supplement requirement.

The most important principle is:

The genotype identifies possible context. The biochemical phenotype shows whether that context is currently visible.

The sequence below is an educational framework for organizing evidence. It is not a diagnostic or treatment protocol.

1. Is fasting homocysteine reproducibly elevated?
2. Are folate and vitamin B12 genuinely adequate?
3. Is kidney function preserved?
4. Could thyroid function, medications, smoking, alcohol, or diet explain part of the result?
5. Is there relevant liver or metabolic disease?
6. Is dietary choline or betaine exposure plausibly low?
7. Were plasma choline, betaine, or DMG measured under interpretable conditions?
8. Is a genetic result being treated as context or as a diagnosis?
9. Was the outcome measured in the research homocysteine, a post-methionine response, liver function, TMAO, or symptoms?
10. Did an objective marker change while other conditions remained stable?

Only after these questions are separated does the BHMT-dependent interpretation become useful.

Where their functions overlap and differ.

Not completely.

TMG can provide betaine directly and may reduce the need to oxidize some choline into betaine under selected conditions.

This may leave more choline available for other functions.

However, TMG cannot directly replace choline needed for:

• phosphatidylcholine;
• sphingomyelin;
• cell membranes;
• lipoprotein assembly;
• acetylcholine;
• fetal and placental development;
• other choline-containing molecules.

There is no validated universal conversion such as:
“A specific number of milligrams of TMG equals one egg yolk.”

Such calculations depend on assumptions about:

• absorption;
• conversion;
• dietary composition;
• endogenous phosphatidylcholine synthesis;
• sex and hormonal status;
• folate and methionine exposure;
• the biological function being considered.

Interpretive takeaway

TMG may substitute for part of choline’s methyl-donor role.
It does not replace choline as an essential nutrient.

Different products can provide different choline-containing compounds.

The number printed on the front of a product does not always equal the amount of actual choline.

No current evidence establishes one choline form as universally best for:

• high homocysteine;
• PEMT variants;
• BHMT variants;
• mood;
• cognition;
• sleep;
• fatty liver;
• pregnancy;
• “methylation support.”

The correct comparison depends on the intended biological outcome.

A product may state:

• 1,200 mg lecithin;
• 1,200 mg phosphatidylcholine;
• a phospholipid blend;
• a percentage of phosphatidylcholine.

These are not automatically equivalent to 1,200 mg of choline.

Phosphatidylcholine contains choline as only one part of the molecule.

Lecithin may contain several different phospholipids.

Therefore, comparisons should distinguish:

• total product weight;
• phosphatidylcholine weight;
• actual choline content;
• serving size;
• other phospholipids and ingredients.

A subjective response to one lecithin product does not prove that every phosphatidylcholine product will produce the same effect.

Betaine anhydrous and TMG

Trimethylglycine and betaine refer to the same core molecule.
Anhydrous betaine is the form used in the principal homocysteine-lowering intervention studies.

Betaine HCl

Betaine hydrochloride is a salt containing betaine and hydrochloride.
It is commonly marketed for gastric-acid support rather than as a standardized homocysteine-lowering intervention.

The major betaine-homocysteine trials did not establish dose equivalence between:

• betaine anhydrous;
• TMG supplements;
• betaine HCl products.

The total mass of betaine HCl is not identical to the mass of betaine.

Products may also contain:

• pepsin;
• digestive enzymes;
• other acids;
• different serving instructions.

A reaction to betaine HCl may involve:

• gastric acidity;
• reflux or mucosal irritation;
• another ingredient;
• betaine exposure;
• the underlying gastrointestinal condition.

It should not automatically be interpreted as a methylation reaction.

One of the largest gaps between published research and online advice involves dosage.

Betaine trials

Human studies examining plasma homocysteine have used exposures including:

• 1.5 g/day;
• 3 g/day;
• 6 g/day;
• study periods commonly lasting several weeks.

In one randomized study, 1.5, 3, and 6 g/day of betaine were compared with placebo for six weeks.

The interventions produced moderate dose-related reductions in fasting homocysteine and larger effects on the rise in homocysteine after a methionine load.

Another randomized study used 6 g/day for six weeks in people with mildly elevated homocysteine.

A meta-analysis of five randomized trials found a pooled reduction in plasma homocysteine, but the included studies generally used at least 4 g/day for six to twenty-four weeks.

Lower dietary-range exposure

Smaller studies have examined:

• approximately 500 mg as a single exposure;
• approximately 1 g/day;
• betaine-rich meals and diets.

These studies suggest that dietary-range exposure can affect plasma betaine and the post-methionine homocysteine response.

They do not establish that a small dose will reliably lower fasting homocysteine in every person.

Phosphatidylcholine trial

One crossover study in healthy men provided phosphatidylcholine corresponding to approximately 2.6 g of choline per day for two weeks.

Fasting homocysteine fell by approximately 18%.

This was a high choline exposure compared with normal dietary reference intakes.

It should not be converted into a routine choline recommendation.

The central limitation

The studies were designed to test group-level biochemical outcomes.

They were not designed to establish:

• a diagnosis of BHMT impairment;
• a personalized starting dose;
• the minimum effective dose for one person;
• lifelong supplementation;
• symptom treatment;
• superiority of a particular commercial product;
• safety of combining several methyl-related supplements.

The study doses are reported to describe the evidence.

They are not individualized recommendations.
Evidence: [B1, B2, B3].

Relevant intervention periods included:

• acute measurements over several hours;
• approximately two weeks;
• six weeks;
• longer periods in selected trials.

The timing depended on the outcome:

• plasma betaine can change rapidly;
• post-methionine homocysteine can change after an acute exposure;
• fasting homocysteine was generally assessed after a defined intervention period;
• lipid changes were observed within weeks in some studies.

An immediate sensation after a capsule is not equivalent to a demonstrated fasting homocysteine response.

Interpretability improves when:

• baseline testing occurs before the intervention;
• exposure and adherence are documented;
• other relevant supplements remain stable;
• repeat testing uses comparable conditions;
• the intended outcome is specified in advance.

Public discussions describe reactions including:

• anxiety;
• agitation;
• irritability;
• insomnia;
• racing thoughts;
• panic;
• depression;
• emotional blunting;
• crying spells;
• fatigue;
• brain fog;
• headache;
• palpitations;
• gastrointestinal discomfort.

These observations can be important.

They have not established a specific clinical syndrome of:

• TMG-induced overmethylation;
• choline-induced overmethylation;
• BHMT overactivation;
• excessive SAM production;
• acetylcholine toxicity at ordinary nutritional exposure.

Several alternatives remain possible.

The exposure may be much larger than expected

A gram-level betaine product is different from the amount obtained from one serving of food.
The amount of actual choline may also differ from the number printed on the product front.

Several active ingredients may be present

Products may include:

• methylfolate;
• methylcobalamin;
• vitamin B6;
• riboflavin;
• niacin;
• stimulants;
• herbs;
• digestive enzymes.

The reaction cannot automatically be assigned to choline or betaine.

The intended pathway may not explain the symptom

BHMT is concentrated mainly in liver and kidney.
Mood, sleep, and cognition involve many additional systems.

Choline has several biological destinations

A response could theoretically involve:

• acetylcholine synthesis;
• membrane phospholipids;
• betaine formation;
• gut microbial metabolism;
• gastrointestinal effects;
• product formulation.

Symptoms alone cannot identify which destination was responsible.

The underlying condition may be changing

Relevant alternatives include:

• sleep loss;
• caffeine;
• medication changes;
• anxiety or mood disorders;
• thyroid dysfunction;
• acute illness;
• psychosocial stress;
• changes in diet or fasting.

What the reaction does not prove

A negative reaction does not automatically prove:

• “overmethylation”;
• slow COMT;
• slow MAOA;
• excessive dopamine;
• excessive serotonin;
• excessive acetylcholine;
• a rapid rise in SAM;
• depletion of glycine;
• depletion of another vitamin;
• successful pathway activation;
• that the product should be continued until adaptation occurs;
• that another choline form will necessarily be tolerated.

Interpretive takeaway

A temporal reaction shows that the exposure deserves reconsideration.
It does not identify the biochemical mechanism.

A severe psychiatric, cardiovascular, neurological, allergic, or gastrointestinal reaction should not be used as a self-experiment or deliberate rechallenge.
Evidence: [U].

The term “choline depression” is commonly used in online discussions to describe:

• low mood;
• emotional flattening;
• anhedonia;
• fatigue;
• reduced motivation;
• brain fog

after eggs, lecithin, phosphatidylcholine, choline salts, alpha-GPC, or citicoline.

These reports do not establish one shared mechanism.

Popular explanations include:

• excessive acetylcholine;
• excessive methyl donation;
• slow COMT;
• changes in dopamine;
• changes in serotonin;
• increased betaine and DMG;
• gut microbial metabolism.

None of these explanations has been validated as a general diagnostic model for supplement-induced depression.

The same symptom can occur for unrelated reasons, and the different choline forms do not have identical pharmacology.

Interpretive takeaway

A reproducible mood reaction is relevant to tolerability. It is not a validated test of acetylcholine status, methylation status, or BHMT function.

There is no validated clinical algorithm that uses COMT or MAOA variants to predict:

• response to TMG;
• response to phosphatidylcholine;
• response to alpha-GPC;
• risk of anxiety;
• risk of insomnia;
• risk of depression;
• the correct choline form;
• the correct dose;
• supplement sequence.

A biochemical connection between methyl metabolism and neurotransmitter metabolism is plausible.
That connection does not establish a genotype-based dosing system.

Common variants may generate research hypotheses.

They do not currently provide a reliable supplement protocol.
Evidence: [U].

The BHMT gene encodes the enzyme that transfers a methyl group from betaine to homocysteine.

Common reports may highlight variants such as:

• rs3733890;
• commercially labelled BHMT-02;
• BHMT-04;
• BHMT-08;
• other tag SNPs.

The presence of a variant does not mean that:

• the enzyme is absent;
• the enzyme is blocked;
• BHMT operates at a known personal percentage;
• TMG will not work;
• a larger TMG dose is required;
• homocysteine is elevated because of that variant;
• psychiatric symptoms originate from BHMT.

Human liver studies show substantial variation in BHMT protein and enzyme activity.

Genetic variation may contribute to some of that variability.

However, no common BHMT SNP provides a validated individual diagnostic or dosing rule.
A report marked “+/+” indicates a genotype according to that reporting system.

It does not mean: “BHMT is completely impaired.”

Interpretive takeaway

BHMT variants can provide context.

They should not replace homocysteine, nutritional, kidney, liver, and response data.
Evidence: [C2].

PEMT produces phosphatidylcholine from phosphatidylethanolamine through a pathway that uses SAM.

This pathway contributes to endogenous phosphatidylcholine synthesis, particularly in the liver.

Commonly discussed PEMT variants include:

• rs7946;
• rs12325817;
• other promoter and coding variants.

Controlled choline-depletion studies support the principle that genetic variation can influence susceptibility to signs of inadequate choline intake.

However, the findings do not create a universal calculator that can determine:

• an exact daily choline requirement;
• an exact number of egg yolks;
• whether phosphatidylcholine is mandatory;
• whether TMG can replace half the requirement;
• whether fatty liver is caused by PEMT;
• whether symptoms are caused by a variant.

The evidence for different PEMT variants is not identical.

Results from one SNP should not automatically be applied to another.

Sex, estrogen status, folate metabolism, methionine intake, pregnancy, and the rest of the diet can also influence choline requirements.

Interpretive takeaway

PEMT variation may modify vulnerability to low choline intake.
It does not diagnose a BHMT bottleneck or provide a precise supplement dose.
Evidence: [B4, C3].

CHDH participates in the oxidation of choline toward betaine.

A CHDH variant may theoretically influence:

• how much choline is directed toward betaine;
• the balance between structural and methyl-donor uses;
• susceptibility during low-choline intake.

Human studies have reported associations between selected CHDH variants and choline-related outcomes.

These associations are not sufficient to calculate:

• an individual percentage of conversion;
• the correct choline form;
• a personal betaine dose;
• the amount of choline “saved” by TMG;
• the cause of elevated homocysteine.

The direction of a genetic effect can also depend on the specific variant and study population.

Not with clinical precision.

Some online calculators combine variants in:

• MTHFR;
• MTHFD1;
• SLC19A1;
• PEMT;
• CHDH;
• BHMT

and convert them into:

• an estimated reduction in methylfolate production;
• a higher calculated choline requirement;
• a number of egg-yolk equivalents;
• an estimated substitution with betaine or TMG.

These tools may help illustrate interactions between folate and choline metabolism. They have not been validated as clinical equations for determining an individual nutrient requirement.

Their estimates generally rely on assumptions such as:

• converting in-vitro enzyme effects into whole-body percentages;
• adding the effects of different SNPs as though they were linear;
• applying group-level depletion studies to one individual;
• assuming a fixed conversion between choline and betaine;
• ignoring differences in absorption, sex, hormonal status, diet, liver function, and current biomarkers.

Egg-yolk equivalents are not a food prescription

An egg-yolk equivalent is only a simplified way of expressing an estimated amount of choline.
Egg yolks are whole foods, not standardized choline doses. Systematically eating several eggs each day also increases exposure to dietary cholesterol, phospholipids, sulfur-containing amino acids, and other nutrients.

Controlled studies show considerable individual variability. Some people have little change in blood lipids, while cholesterol hyperresponders may experience a more pronounced rise in LDL cholesterol. This may be particularly relevant when LDL or ApoB is already elevated. [B7, C4]

The conversion of egg-derived choline into TMAO also varies according to gut microbiota, kidney function, dose, and testing conditions. Some studies have found an acute post-meal rise, while longer trials in healthy participants with normal kidney function have not consistently found an increase in fasting TMAO. [B5, C6]

Eggs also provide methionine and cysteine. These are normal essential components of the diet, but gastrointestinal tolerance may differ in people with sulfur-sensitive or hydrogen-sulfide-related symptoms. Current evidence does not support diagnosing a specific “high-sulfate metabolism” from symptoms, urinary sulfate, or common genetic variants alone. [U]

Interpretive takeaway

A genetic calculator may generate a hypothesis about dietary attention. It does not measure a personal choline requirement, and its egg-yolk estimate should not be treated as a validated instruction to consume several eggs every day.
Evidence: [B5, B7, C4, C6, U].

Folate- and choline-related methyl metabolism are interconnected.

When folate availability is low, more choline may be directed toward betaine-dependent methyl donation.
When choline availability is low, folate-dependent remethylation may carry more of the methyl-donor burden.

This creates a genuine nutrient interaction.

It does not justify a rigid rule such as:

• MTHFR always doubles choline requirements;
• TMG always replaces half of choline;
• folate can fully replace choline;
• choline can fully replace folate.

Choline remains necessary for structural functions even when folate status is excellent.
Folate remains necessary for folate-dependent reactions even when betaine lowers homocysteine.

Creatine synthesis consumes methyl groups.

Providing creatine can reduce endogenous creatine synthesis and may alter methyl-group demand.
This is a legitimate biochemical concept.

It does not establish that creatine:

• corrects limited choline intake;
• replaces betaine;
• normalizes BHMT activity;
• permits a predictable reduction in dietary choline;
• treats a methylation disorder;
• prevents reactions to choline or TMG.

No validated calculator converts creatine intake into a precise reduction in choline or TMG requirements.

A mildly elevated homocysteine result may fluctuate.
Repeat testing and consistent conditions matter.

If riboflavin, methylfolate, B12, TMG, choline, creatine, and diet all changed, the result cannot be assigned to riboflavin.

Riboflavin may alter homocysteine without improving:

• anxiety;
• fatigue;
• cognition;
• sleep;
• mood;
• exercise tolerance.

Interpretive takeaway

Failure of homocysteine to change should weaken or complicate the original riboflavin-sensitive hypothesis.
It does not automatically indicate that a higher dose, R5P, or FAD is required.

How individual context changes interpretation

What are TMA and TMAO?

TMA, or trimethylamine, is a volatile compound with a characteristic fishy odor. Certain gut bacteria can produce it from choline and other trimethylamine-containing nutrients.

After TMA is absorbed from the intestine, the liver enzyme FMO3 converts most of it into TMAO, or trimethylamine N-oxide. TMAO is less volatile and is eliminated mainly through the kidneys.

The pathway can therefore be summarized as:Dietary precursor → gut microbial TMA → liver conversion to TMAO → kidney excretion

A blood TMAO result may be influenced at several stages:

• how much precursor reaches TMA-producing bacteria;
• which gut microbes are present;
• how efficiently the liver converts TMA into TMAO;
• how efficiently the kidneys clear TMAO.

TMA and TMAO are not interchangeable measurements. TMA accumulation is mainly relevant when conversion by FMO3 is substantially impaired, as in trimethylaminuria. Ordinary production of some TMA after eating choline-containing food does not by itself indicate this disorder.

First, gut microbes can convert certain choline-containing compounds into trimethylamine, or TMA. The liver then converts TMA into TMAO.

A blood TMAO result reflects both:

• how much TMA is produced;
• how efficiently TMAO is cleared, mainly by the kidneys.

It is therefore not a direct measure of choline toxicity, cardiovascular damage, or excessive methylation.

TMAO interpretation is complex because concentrations are influenced by:

• kidney function;
• gut microbial composition;
• the chemical form of choline;
• food matrix;
• recent diet;
• liver oxidation;
• urinary excretion;
• other TMA-containing foods.

Do all choline forms produce the same TMAO response?

No.

Randomized human studies have reported different TMAO responses to different forms.

In one trial involving participants with normal kidney function:

• choline bitartrate increased fasting TMAO;
• four eggs per day did not significantly increase fasting TMAO;
• phosphatidylcholine supplements did not significantly increase fasting TMAO.

Other small crossover studies have also found that water-soluble choline forms can produce a different acute TMAO response from phosphatidylcholine.

These findings should not be converted into a universal claim that:

• eggs never raise TMAO;
• phosphatidylcholine is always risk-free;
• choline bitartrate causes cardiovascular disease;
• a temporary TMAO rise predicts a clinical event;
• one form is best for every person.

Does a higher TMAO result prove that choline is harmful?

No.

TMAO is associated with cardiovascular and renal outcomes in observational research, but causal interpretation in an individual remains difficult.

Kidney function is an especially important confounder because reduced clearance can raise TMAO.

The practical distinction

The question is not simply:

“Does this molecule contain choline?”

The more useful questions are:

• which chemical form was used;
• what dose was used;
• was it food or a supplement;
• was kidney function normal;
• was fasting or post-dose TMAO measured;
• did any clinically meaningful outcome change?

Evidence: [B5].

Lower homocysteine should not automatically be interpreted as lower cardiovascular risk.

In randomized studies of healthy adults:

• 6 g/day of betaine for six weeks increased LDL cholesterol and triglycerides;
• changes at 1.5 and 3 g/day were smaller and did not consistently reach statistical significance;
• lipid changes appeared within weeks;
• phosphatidylcholine providing approximately 2.6 g/day of choline increased triglycerides modestly in one short trial without increasing cholesterol.

These findings do not prove that ordinary dietary betaine or choline is harmful.

They do show that a biomarker benefit in one pathway may coexist with an unfavorable change in another marker.

A fall in homocysteine does not by itself establish net cardiovascular benefit.

Interpretive takeaway

Homocysteine, LDL, triglycerides, ApoB, blood pressure, kidney function, diet, and overall risk should not be collapsed into one methylation narrative.
Evidence: [B6, A3].

Choline is required for phosphatidylcholine synthesis.

Phosphatidylcholine is important for:

• cell membranes;
• lipoprotein assembly;
• export of triglycerides from the liver.

Controlled depletion studies have shown that some adults develop:

• fatty liver;
• elevated liver enzymes;
• muscle injury

when fed a low-choline diet.

Susceptibility varies by:

• sex;
• menopausal status;
• estrogen exposure;
• genetic variation;
• folate metabolism;
• other dietary factors.

What this evidence supports

Genuine choline inadequacy can affect liver and muscle function.

What it does not support

Fatty liver does not automatically prove:

• choline deficiency;
• PEMT impairment;
• BHMT impairment;
• a need for phosphatidylcholine supplements;
• a need for TMG;
• that other causes can be ignored.

Fatty liver can also be influenced by:

• insulin resistance;
• body weight;
• alcohol;
• medications;
• viral disease;
• genetic factors;
• total energy intake;
• several interacting causes.

Pale stools, reflux, bloating, or discomfort after fatty foods do not diagnose choline deficiency or poor bile flow.
Evidence: [A2, B4].

Choline has important roles in:

• cell division;
• membrane formation;
• placental function;
• fetal brain development;
• one-carbon metabolism.

Official Adequate Intakes are approximately:

• 450 mg/day during pregnancy;
• 550 mg/day during lactation.

These are population reference values, not individualized treatment targets.

Pregnancy does not create a validated protocol based on:

• MTHFR;
• PEMT;
• BHMT;
• CHDH;
• a choline calculator;
• egg-yolk equivalents.

Betaine cannot replace all pregnancy-related functions of choline.

TMG should not be used to assume that structural choline needs have been covered.

There is also no validated genotype-specific high-dose TMG protocol for ordinary pregnancy.

Pregnancy-related supplementation and abnormal homocysteine require appropriate obstetric and nutritional assessment rather than self-directed methylation experimentation.
Evidence: [A2].

A vegan diet can provide choline and betaine, but the pattern of intake differs from an omnivorous diet.

Relevant plant sources can include:

• soy foods;
• beans;
• cruciferous vegetables;
• nuts and seeds;
• whole grains;
• wheat germ;
• quinoa;
• spinach;
• beets.

Risk becomes more plausible when a restrictive diet also includes:

• low total food intake;
• limited legumes and soy;
• avoidance of grains;
• limited vegetables;
• vitamin B12 inadequacy;
• low protein intake;
• pregnancy or lactation;
• malabsorption;
• several simultaneous exclusions.

In a person with elevated homocysteine, a vegan diet should not lead directly to the conclusion that choline is the limiting nutrient.

Vitamin B12 status is a major competing explanation.

The limited-availability hypothesis becomes more plausible when:

• fasting homocysteine is repeatedly elevated;
• dietary choline or betaine exposure is plausibly low;
• plasma betaine is low or marginal;
• folate and B12 have been assessed adequately;
• kidney and thyroid function do not provide a stronger explanation;
• major liver disease does not make the pattern uninterpretable;
• homocysteine falls after documented betaine exposure under stable conditions.

The hypothesis becomes less convincing when:

• homocysteine is consistently normal;
• dietary exposure is adequate;
• folate or B12 deficiency is clear;
• kidney dysfunction explains the elevation;
• substantial betaine exposure does not alter the objective pattern;
• the conclusion depends mainly on SNPs;
• the conclusion depends mainly on symptoms;
• several supplements were introduced simultaneously.

If homocysteine falls

This supports a betaine-responsive component.

It does not prove an initial betaine deficiency or BHMT impairment.

If homocysteine does not fall

The original hypothesis becomes weaker or more complicated.

A larger dose is not automatically the correct interpretation.

If symptoms improve but biomarkers do not change

The response may involve another function of choline or betaine, expectancy, another ingredient, or natural symptom variation.

If symptoms worsen

The reaction is relevant to tolerability.

It does not establish overmethylation.

If genetic variants are present but biomarkers are normal

The genotype changes context.

It does not establish a disorder requiring treatment.

If fatty liver is present

Choline status may be relevant, but the condition requires broader interpretation.

Is fasting homocysteine elevated more than once?
Were the tests performed under comparable fasting conditions?
Were choline, TMG, folate, B12, creatine, or other supplements used before testing?
Is serum folate high because of recent supplementation?
Has vitamin B12 been assessed with enough context?
Is methylmalonic acid relevant?
Are creatinine and eGFR adequate?
Could hypothyroidism explain part of the result?
Are liver markers, triglycerides, glucose regulation, or imaging relevant?
Is dietary choline intake genuinely low?
Is dietary betaine intake genuinely low?
Are plasma choline, betaine, and DMG available?
Could the plasma result mainly reflect recent supplementation?
Which BHMT, PEMT, or CHDH variant is actually present?
Is a commercial “+/+” result being treated as complete enzyme failure?
Is an online calculator being treated as a validated requirement test?
Which choline form is being used?
How much actual choline does the product provide?
Is the product betaine anhydrous or betaine HCl?
Were several methyl-related supplements started together?
Was the intended outcome fasting homocysteine, post-methionine homocysteine, liver function, TMAO, lipids, or symptoms?
Did the objective marker change?
Did symptoms and laboratory markers move in the same direction?
Did LDL cholesterol or triglycerides change during gram-level betaine exposure?
Is a TMAO result being interpreted without considering kidney function and supplement form?
What finding would make the limited-availability interpretation less likely?
These are different questions.
They require different evidence and may lead to different conclusions.

High-confidence sources

[A1] BHMT reaction and tissue distribution

Sources
Garrow TA. Purification, kinetic properties, and cDNA cloning of mammalian betaine-homocysteine methyltransferase. Journal of Biological Chemistry. 1996.
Sunden SLF, Renduchintala MS, Park EI, Miklasz SD, Garrow TA. Betaine-homocysteine methyltransferase expression in porcine and human tissues and chromosomal localization of the human gene. Archives of Biochemistry and Biophysics. 1997;345:171–174. PMID: 9281325.

Used to support

• transfer of a methyl group from betaine to homocysteine;
• production of methionine and dimethylglycine;
• high expression of BHMT in liver and kidney;
• separation of BHMT-dependent and folate–B12-dependent remethylation.

Does not establish

• a clinical diagnosis of BHMT impairment;
• a personal enzyme-activity percentage;
• symptom causation;
• an individual betaine dose.

[A2] Choline physiology, dietary reference values, deficiency, and safety

Sources
National Institutes of Health, Office of Dietary Supplements. Choline: Fact Sheet for Health Professionals.
Institute of Medicine. Dietary Reference Intakes for Choline.

Used to support

• choline as an essential nutrient;
• endogenous phosphatidylcholine synthesis being insufficient to meet all human needs;
• formation of phosphatidylcholine, sphingomyelin, acetylcholine, and betaine;
• adult Adequate Intakes;
• pregnancy and lactation values;
• variability in choline requirements;
• limitations of plasma choline;
• adult Tolerable Upper Intake Level;
• adverse effects associated with excessive exposure.

Does not establish

• an individualized choline requirement;
• a genotype-based requirement;
• a treatment protocol for elevated homocysteine;
• superiority of a supplement form.

[A3] Formal safety assessment of supplemental betaine

Sources
European Food Safety Authority Panel. Safety of betaine as a novel food pursuant to Regulation (EC) No 258/97. EFSA Journal. 2017;15:5057.
European Food Safety Authority Panel. Safety of betaine as a novel food pursuant to Regulation (EU) 2015/2283. EFSA Journal. 2019;17:5658.

Used to support

• distinction between dietary betaine and supplemental novel-food exposure;
• limited safety database for high supplemental intake;
• concern about lipid changes at several-gram exposures;
• the importance of not treating the absence of acute symptoms as proof of unlimited safety.

Does not establish

• an individual therapeutic dose;
• treatment of elevated homocysteine;
• safety of all commercial TMG products or combinations.

Moderate-confidence human intervention evidence

[B1] Betaine and mildly elevated homocysteine

Source
Steenge GR, Verhoef P, Katan MB. Betaine supplementation lowers plasma homocysteine in healthy men and women. Journal of Nutrition. 2003;133:1291–1295. PMID: 12730412.
Design
Randomized comparison of:

• 6 g/day betaine;
• folic acid;
• placebo;
• six-week intervention.

What it showed

• betaine lowered fasting homocysteine;
• betaine reduced the post-methionine homocysteine response.

What it did not show

• symptom improvement;
• prevention of cardiovascular events;
• diagnosis of betaine deficiency;
• lifelong need for betaine;
• benefit from larger doses.

[B2] Dose-related betaine response

Source
Olthof MR, van Vliet T, Boelsma E, Verhoef P. Low-dose betaine supplementation leads to immediate and long-term lowering of plasma homocysteine in healthy men and women. Journal of Nutrition. 2003;133:4135–4138. PMID: 14652361.
Design
Randomized exposure to:

• 1.5 g/day;
• 3 g/day;
• 6 g/day;
• placebo;
• six weeks.

What it showed

• moderate dose-related reduction in fasting homocysteine;
• larger effects on the rise after methionine loading.

What it did not show

• a minimum effective dose for one individual;
• treatment of symptoms;
• the presence of BHMT impairment;
• superiority of a commercial TMG product.

[B3] Phosphatidylcholine and homocysteine

Source
Olthof MR, Brink EJ, Katan MB, Verhoef P. Choline supplemented as phosphatidylcholine decreases fasting and postmethionine-loading plasma homocysteine concentrations in healthy men. American Journal of Clinical Nutrition. 2005;82:111–117.
Design
Crossover trial in healthy men using phosphatidylcholine that provided approximately:

• 2.6 g/day of choline;
• for two weeks.

What it showed

• fasting homocysteine fell by approximately 18%;
• post-methionine homocysteine also decreased.

What it did not show

• that ordinary dietary choline produces the same effect;
• a routine supplement dose;
• superiority of phosphatidylcholine;
• treatment of a diagnosed BHMT disorder.

[B4] Controlled choline depletion and repletion

Sources
Fischer LM, da Costa KA, Kwock L, et al. Sex and menopausal status influence human dietary requirements for the nutrient choline. American Journal of Clinical Nutrition. 2007;85:1275–1285.
da Costa KA, Kozyreva OG, Song J, Galanko JA, Fischer LM, Zeisel SH. Common genetic polymorphisms affect the human requirement for the nutrient choline. FASEB Journal. 2006;20:1336–1344. PMID: 16816108.

Used to support

• development of liver or muscle abnormalities during controlled choline depletion in susceptible participants;
• differences by sex and menopausal status;
• the principle that genetic variation can modify susceptibility.

Does not establish

• a precise individual requirement;
• a number of egg-yolk equivalents;
• a diagnosis from rs7946 alone;
• a betaine replacement ratio;
• a BHMT-specific disorder.

[B5] Choline form and TMAO response

Source
Wilcox J, Skye SM, Graham B, et al. Dietary choline supplements, but not eggs, raise fasting TMAO levels in participants with normal renal function: a randomized clinical trial. American Journal of Medicine. 2021. PMID: 33872583.

What it showed in the studied population

• choline bitartrate increased fasting TMAO;
• four eggs daily did not significantly increase fasting TMAO;
• phosphatidylcholine supplements did not significantly increase fasting TMAO.

What it did not show

• long-term cardiovascular outcomes;
• universal safety of eggs or phosphatidylcholine;
• universal harm from choline bitartrate;
• effects in people with reduced kidney function.

[B6] Betaine, phosphatidylcholine, and blood lipids

Source
Olthof MR, van Vliet T, Verhoef P, Zock PL, Katan MB. Effect of homocysteine-lowering nutrients on blood lipids: results from four randomised, placebo-controlled studies in healthy humans. PLoS Medicine. 2005;2:e135. PMID: 15916468.

What it showed

• 6 g/day betaine increased LDL cholesterol and triglycerides;
• smaller betaine doses showed smaller, statistically uncertain lipid changes;
• high-dose phosphatidylcholine modestly increased triglycerides in one short study.

What it did not show

• harm from ordinary food intake;
• long-term cardiovascular-event risk;
• the net clinical effect of lowering homocysteine.

[B7] Individual lipid responses to dietary cholesterol from eggs

Source
Herron KL, Vega-Lopez S, Conde K, Ramjiganesh T, Shachter NS, Fernandez ML. Men classified as hypo- or hyperresponders to dietary cholesterol feeding exhibit differences in lipoprotein metabolism. Journal of Nutrition. 2003;133(4):1036–1042. PMID: 12672915. DOI: 10.1093/jn/133.4.1036.
Design
Randomized crossover study involving 40 normolipidemic men.
Participants received:

• an egg diet providing approximately 640 mg/day of additional dietary cholesterol;
• a placebo diet without additional cholesterol;
• two 30-day intervention periods separated by a three-week washout.

What it showed

• participants differed substantially in their lipid response;
• 15 participants were classified as hyperresponders;
• LDL and HDL cholesterol increased significantly in hyperresponders;
• 25 hyporesponders showed no significant increase in LDL or HDL cholesterol.

Used to support

• genuine individual variability in the lipid response to sustained egg-derived dietary cholesterol;
• the limitation of treating egg-yolk equivalents as metabolically neutral dosing units.

Does not establish

• that eggs are harmful for everyone;
• long-term cardiovascular-event risk;
• the proportion of hyperresponders in the general population;
• that a choline-related genetic calculator can predict the lipid response.

Limited and context-dependent evidence

[C1] Plasma choline, betaine, and DMG as biomarkers

Source types

• analytical validation studies;
• controlled feeding studies;
• observational studies;
• short supplementation studies.

Used to support

• laboratory measurability;
• response to recent intake and supplementation;
• possible value in describing pathway context.

Does not establish

• direct BHMT flux;
• tissue choline status;
• universal diagnostic thresholds;
• an individual supplement requirement.

[C2] BHMT genotype–phenotype relationships

Source
Feng Q, Kalari K, Fridley BL, et al. Betaine-homocysteine methyltransferase: human liver genotype-phenotype correlation. Molecular Genetics and Metabolism. 2011;102:126–133. PMID: 21093336.

What it showed

• substantial variation in human hepatic BHMT protein and activity;
• selected genetic associations with hepatic measurements.

What it did not establish

• a diagnostic rule for common SNPs;
• complete enzyme failure from a “+/+” report;
• a TMG dose;
• prediction of symptoms or supplement tolerance.

[C3] PEMT and CHDH variation

Source types

• controlled depletion studies;
• tracer studies;
• observational genetic associations;
• small nutrigenetic studies.

Used to support

• the principle that common variants can influence choline metabolism;
• possible differences in susceptibility under low-choline conditions.

Does not establish

• exact milligram requirements;
• a clinically validated calculator;
• a required supplement form;
• symptom causation.

[C4] One egg per day and marked LDL response in a subgroup

Source
Chakrabarty G, Manjunatha S, Bijlani RL, et al. The effect of ingestion of egg on the serum lipid profile of healthy young Indians. Indian Journal of Physiology and Pharmacology. 2004;48(3):286–292. PMID: 15648400.
Design
Randomized controlled crossover study involving 34 healthy young adults.
Participants consumed:

• one boiled egg per day;
• for eight weeks;
• compared with an egg-free dietary period.

What it showed

• the average group result concealed substantial individual variability;
• 12 of 34 participants experienced an LDL-cholesterol increase greater than 15%;
• these participants also showed increases in total cholesterol;
• the remaining 22 participants showed no meaningful change in the measured lipid variables.

Important limitation
The study was small, involved a specific young Indian population, and used an author-defined 15% threshold to classify hyperresponders.

Used to support

• the possibility that even one egg per day may produce a pronounced LDL response in some individuals;
• the importance of not converting egg-yolk equivalents into a universal daily food prescription.

Does not establish

• that approximately one-third of all people are hyperresponders;
• long-term cardiovascular harm;
• that the same response will occur in other populations;
• which genes reliably predict the response.

[C6] Acute egg-yolk intake and individual TMAO production

Source
Miller CA, Corbin KD, da Costa KA, et al. Effect of egg ingestion on trimethylamine-N-oxide production in humans: a randomized, controlled, dose-response study. American Journal of Clinical Nutrition. 2014;100(3):778–786. PMID: 24944063. DOI: 10.3945/ajcn.114.087692.
Design
Randomized acute dose-response study involving six healthy volunteers.
Participants consumed:

• 0, 1, 2, 4, or 6 egg yolks;
• on separate study days;
• with more than two weeks between exposures;
• against a controlled low-choline dietary background.

What it showed

• two or more egg yolks increased plasma and urinary TMAO;
• approximately 14% of total dietary choline was estimated to be converted into TMAO;
• the TMAO response differed substantially between participants;
• equivalent exposures produced at least a fourfold difference in TMAO production between individuals;
• no acute increase in hsCRP or oxidized LDL was detected after the egg doses.

Used to support

• individual variability in the conversion of egg-derived choline into TMAO;
• the influence of gut microbial and host metabolic factors;
• the limitation of predicting the TMAO response from the number of egg yolks alone.

Does not establish

• harm from chronic egg consumption;
• that a temporary TMAO rise causes cardiovascular disease;
• responses in people with impaired kidney function;
• long-term changes in inflammation or oxidized LDL;
• that common methylation variants predict TMAO production.

Preliminary and mechanistic evidence

[D] Pathway allocation and tissue-specific models
Mechanistic and tracer studies support:

• competition between structural and methyl-donor uses of choline;
• interaction between folate and choline pathways;
• possible changes in substrate partitioning;
• tissue-specific regulation.

These findings do not provide:

• a routine clinical BHMT-flux test;
• a whole-body methylation measurement;
• an individualized treatment protocol.

Unverified explanations

[U] Popular claims not established by current evidence
The following ideas reflect real user questions but should not be treated as established conclusions:

• BHMT “+/+” means the enzyme is blocked;
• BHMT variants mean TMG will not work;
• BHMT variants mean a larger TMG dose is required;
• PEMT rs7946 means the body cannot produce phosphatidylcholine;
• a genetic calculator can calculate an exact choline requirement;
• TMG can replace half of all choline needs;
• a fixed amount of TMG equals one egg yolk;
• TMG repairs MTHFR;
• a homocysteine response proves betaine deficiency;
• no homocysteine response proves BHMT failure;
• anxiety after TMG proves overmethylation;
• depression after choline proves acetylcholine excess;
• COMT predicts choline or TMG tolerance;
• glycine or niacin is a validated antidote to a methylation reaction;
• high DMG proves excessive BHMT activity;
• low plasma choline proves deficiency in every tissue;
• normal plasma choline proves adequate total-body status;
• fatty liver proves PEMT or choline deficiency;
• pale stools prove inadequate phosphatidylcholine;
• one choline form is universally free of TMAO risk;
• lower homocysteine automatically means lower cardiovascular risk;
• symptom improvement proves restoration of methylation.

These explanations may contain a biochemical idea worth investigating.
They do not establish diagnosis, mechanism, dosage, clinical benefit, or safety.

The choline-betaine-BHMT pathway is biochemically real.

Its central reaction is well established:

Betaine donates a methyl group to homocysteine through BHMT, producing methionine and dimethylglycine.

Human intervention studies show that betaine can lower plasma homocysteine.

High-dose phosphatidylcholine can also lower homocysteine, presumably in part because some choline is converted into betaine.

This makes the pathway:

• biologically valid;
• measurable through selected metabolites;
• responsive to dietary and supplemental exposure.

It does not make “BHMT impairment” a validated routine diagnosis.

The pattern is not established simply because:

• homocysteine is elevated;
• an MTHFR variant is present;
• BHMT is marked “+/+”;
• PEMT rs7946 appears in a report;
• a calculator recommends eight egg yolks;
• TMG lowers homocysteine;
• choline improves cognition;
• TMG causes anxiety;
• eggs cause insomnia;
• fatty liver is present;
• plasma choline is low;
• DMG is high;
• a person identifies as an “undermethylator” or “overmethylator.”

The strongest interpretation requires:

• a compatible and reproducible laboratory phenotype;
• realistic dietary assessment;
• adequate evaluation of folate and B12;
• consideration of kidney, liver, thyroid, medication, and lifestyle factors;
• cautious interpretation of choline, betaine, and DMG;
• separation of genetic context from current function;
• an objective response measured under stable conditions.

The most useful question is not:

“Is my BHMT gene blocked, and how much TMG do I need?”

It is:

Do the laboratory, dietary, and response findings make limited choline or betaine availability a plausible contributor to homocysteine elevation, and is that explanation more convincing than folate, B12, kidney function, liver metabolism, or another cause?